Previous research has established that trace minerals are necessary for optimal animal health and performance. The objective of this study was to evaluate the effect of an injectable trace mineral supplement containing copper, zinc, selenium, and manganese (Multimin 90) on vaccine response, growth performance and morbidity of beef calves upon entry into a feedlot. A total of 128 crossbred bull (n = 40) and steer (n = 88) calves were utilized. Cattle were stratified by initial BW (276 ± 3 kg) and gender, then assigned randomly to treatment pens (n = 8/treatment). Treatment protocols were (1) negative control (CON), or (2) Multimin 90 (MM) administered at 1 mL/45.5 kg BW subcutaneously on d 0. Cattle were also administered a pentavalent modified-live respiratory vaccine, anthelmintic, and metaphylaxis with tilmicosin phosphate on d 0. Individual BW data and blood were collected on d 0, 14, 28, and 42. Harvested serum was used to determine bovine viral diarrhea virus (BVDV) type 1a antibody titer as a proxy for vaccine response. Health was monitored daily by trained personnel blinded to treatment pen assignment. Calves were pulled when assigned a clinical illness score of ≥ 2, and considered morbid and administered antimicrobial treatment if rectal temperature was ≥ 39.7°C or if lung auscultation score was ≥ 3 on a 1 to 5 scale. Overall DMI was not different (P = 0.82) between CON and MM. Also, no difference in overall ADG (P = 0.21) was detected between CON (1.36 kg/d) and MM (1.25 kg/d) steers. The overall morbidity rate observed for this study was low (14%). There was no statistical difference (P = 0.71) in morbidity between treatments, which averaged 15.6 and 12.5%, for CON and MM, respectively. There was a treatment x d effect (P = 0.09) for BVDV-specific antibody titer. On d 14, the MM group had a greater (P = 0.02) BVDV antibody titer than the CON group. This data suggests that while administration of an injectable trace mineral did not improve performance or morbidity rate when disease incidence was low, the BVDV-specific antibody response to a respiratory vaccine developed faster for Multimin 90 treated animals.